)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Iovance Biotherapeutics
Iovance Biotherapeutics (IOVA) investor relations material
Iovance Biotherapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary24 Feb, 2026
Executive summary
Achieved 30% quarterly revenue growth in Q4 2025 and 61% year-over-year for the full year, driven by strong AMTAGVI demand, operational improvements, and expanded ATC network.
Full-year 2025 revenue reached $264 million, meeting annual guidance, with gross margin improving to 50% in Q4 due to operational efficiencies and internalized manufacturing.
Advanced pipeline with lifileucel showing strong efficacy in non-small cell lung cancer and sarcoma, including FDA Fast Track designation and positive early/interim data.
Extended cash runway into Q3 2027 through cost optimization, disciplined capital use, and a year-end cash position of $303 million.
Amtagvi approved in Canada, with regulatory submissions underway in the UK, Australia, and Switzerland.
Financial highlights
Q4 2025 product revenue reached $87 million, up 30% sequentially; full-year revenue totaled $264 million, with Amtagvi contributing $220 million (US) and Proleukin $44 million (global).
Q4 gross margin improved to 50% from 43% in Q3, reflecting operational optimization and internalized manufacturing.
Proleukin contributed about 17% of total revenue for 2025, with ordering patterns stabilizing.
Cash position at year-end was $303 million, supporting operations into Q3 2027.
Net loss for FY25 was $390.98 million; Q4 net loss was $71.9 million.
Outlook and guidance
Expecting remarkable revenue growth in 2026, primarily from AMTAGVI, with formal guidance to be provided soon.
Operational improvements and internalized manufacturing expected to further enhance margins and reduce costs in 2026–2027.
Preparing for commercial launches in new indications, including non-small cell lung cancer and sarcoma, with potential U.S. launch for lung cancer in 2H 2027.
Global expansion underway, with AMTAGVI approved in Canada and pending approvals in the U.K., Australia, and Switzerland.
Quantify 2026/27 operating expense improvements
Amtagvi ex-US revenue contribution forecast
Lifileucel NSCLC market penetration strategy
What drives future gross margin improvement?
Community ATC ramp-up timeline and drivers?
Sarcoma registrational trial patient numbers?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Iovance Biotherapeutics earnings date
TD Cowen 46th Annual Health Care Conference2 Mar, 2026
Iovance Biotherapeutics
Next Iovance Biotherapeutics earnings date
TD Cowen 46th Annual Health Care Conference2 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Iovance Biotherapeutics Inc is a biotechnology company focused on developing cell-based immunotherapies for the treatment of cancer. The company specializes in tumor-infiltrating lymphocyte (TIL) therapies, which involve harnessing and enhancing a patient's immune cells to target and destroy cancer cells. Iovance’s research primarily targets solid tumors, aiming to offer new treatment options for patients with melanoma, cervical cancer, and other types of cancers. Its therapies are developed using advanced cell therapy technologies to address cancers that are resistant to traditional treatments. The company is headquartered in San Carlos, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage